Innohep (Tinzaparin Sodium)

Tinzaparin sodium enhances the activity of antithrombin III, which then inhibits factor Xa and, to a lesser extent, factor IIa (thrombin). By blocking these key steps in the coagulation cascade, the drug reduces fibrin formation and limits clot development.

The specific dose of Innohep is determined by the prescribing clinician based on the patient’s indication, weight, renal function, and risk factors. Healthcare professionals calculate the appropriate regimen and adjust it as needed during therapy.

The pregnancy safety category for tinzaparin sodium is not definitively established. It may be used during pregnancy only when the potential maternal benefit outweighs any possible risk to the fetus, and it is generally avoided during breastfeeding unless clearly indicated by a physician.

To order Innohep, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with unfractionated heparin, tinzaparin offers more predictable pharmacokinetics, a longer half‑life and does not usually require routine laboratory monitoring. Relative to other LMWHs, it has a higher anti‑Xa to anti‑IIa ratio, which may influence dosing in certain renal‑impairment scenarios.

Innohep should be stored below 25 °C in its original packaging, protected from moisture and direct light. Do not refrigerate or freeze the product. Keep the vial or pre‑filled syringe sealed until use and discard any solution that appears discoloured or cloudy.

Innohep is given by subcutaneous injection, typically into the abdominal wall or thigh. The injection site should be rotated to minimise local irritation. Administration is performed by a trained healthcare professional following aseptic technique and the dosage prescribed by the clinician.

The most serious risks include major bleeding events, heparin‑induced thrombocytopenia (HIT), and rare spinal or epidural haematomas, especially after neuraxial procedures. Patients should be monitored for signs of bleeding, sudden platelet count drops, or neurological symptoms.

Innohep is contraindicated in patients with active major bleeding, a known history of HIT, severe uncontrolled hypertension, or hypersensitivity to tinzaparin or any heparin product. Caution is also advised for those with severe renal impairment or recent major surgery.